HARROW, INC.: management transactions · United States · SEC (Form 4)

About HARROW, INC.

Harrow, Inc. (NASDAQ: HROW) is a U.S.-based ophthalmology-focused healthcare company operating in a specialized but economically attractive segment of pharmaceuticals. Headquartered in Nashville, Tennessee, in the United States, Harrow was originally founded in 2012 in San Diego, California, and later shifted its corporate center to Nashville as the company expanded. Over time, Harrow has evolved from a business centered on compounded ophthalmic medicines into an integrated platform serving eyecare professionals across surgical, in-office, and chronic-care use cases. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-nashville-expansion/?utm_source=openai)) The company’s operating model is built around ophthalmic disease management solutions for the North American market. Harrow’s portfolio spans conditions affecting both the front and back of the eye, including dry eye disease, ocular inflammation, cataracts, glaucoma, allergic conjunctivitis, infections, and selected retinal indications. The company markets a mix of branded prescription medicines and compounded formulations through its commercial infrastructure and pharmacy relationships. Key products and brands highlighted by Harrow include VEVYE, IHEEZO, IOPIDINE, MAXITROL, MOXEZA, ILEVRO, NEVANAC, MAXIDEX, FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and recently added assets such as BYQLOVI. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)) From a competitive standpoint, Harrow occupies a differentiated position in U.S. ophthalmology because it combines branded products, compounding capabilities, and direct commercial reach. That combination gives the company exposure to both recurring chronic-use therapies and procedure-related products, while also allowing it to support eyecare physicians with a broad product toolkit. Harrow describes itself as a leading provider of ophthalmic disease management solutions in North America and continues to position its platform around affordability, accessibility, and improved clinical outcomes. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)) Recent corporate developments underscore a deliberate portfolio-expansion strategy. In 2024, Harrow announced the U.S. availability of VEVYE and expanded access through the 340B Prime Vendor Program. In 2025, the company announced the acquisition of U.S. commercial rights to BYQLOVI, a clobetasol propionate ophthalmic suspension positioned as the first new ophthalmic steroid in its class in more than 15 years. These moves support Harrow’s broader effort to deepen its ophthalmic franchise, broaden market access, and strengthen its commercial footprint on the NASDAQ-listed market in the United States. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-availability-vevyer-cyclosporine-ophthalmic/?utm_source=openai))